Nemaura Medical to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will present an overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference from January 10-13, 2022. The presentation will be available on-demand for registered attendees starting at 7:00 a.m. ET on January 10. Nemaura focuses on developing non-invasive wearable diagnostic devices, including the CE-marked sugarBEAT® and proBEAT™, aiding diabetes management. The global Type 2 diabetes market is projected to reach $59 billion by 2025, presenting significant growth opportunities.

Loughborough, England, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

The presentation will be available on-demand beginning at 7:00 a.m. ET on Monday, January 10, 2022, to H.C. Wainwright registered attendees of the conference.

Register for the conference here: https://hcwevents.com/bioconnect/

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

What is Nemaura Medical's presentation at the H.C. Wainwright Bioconnect 2022 Virtual Conference about?

Nemaura Medical's CEO will provide a corporate overview at the conference, focusing on the company's innovations in non-invasive wearable diagnostic devices.

When will Nemaura Medical's presentation be available for conference attendees?

The presentation will be available on-demand starting at 7:00 a.m. ET on January 10, 2022.

What products does Nemaura Medical offer?

Nemaura Medical offers the non-invasive glucose monitor sugarBEAT® and proBEAT™, which combines glucose data and digital healthcare services.

What markets is Nemaura Medical targeting?

The company is targeting the Type 2 diabetes market, expected to reach $59 billion by 2025, and the pre-diabetic market, valued over $50 billion.

How can I register for the H.C. Wainwright Bioconnect 2022 conference?

You can register for the conference by visiting H.C. Wainwright's official website.